Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2014

View Archived Issues

Development of a rapid MRR test for the detection of malaria

Opexa Therapeutics to target neuromyelitis optica

AstraZeneca presents novel TMK inhibitors with antibacterial activity

Asubio Pharma presents promising preclinical data for ASB-14780

S1P1 functional antagonist demonstrates utility for multiple sclerosis

Almirall discloses novel PI3Kdelta inhibitors

Novel BACE1 inhibitors reported by Pfizer

Bayer Schering Pharma synthesizes new Mnk1 inhibitors

New mutation in the NARS2 gene linked to OXPHOS deficiencies

High prevalence of p.R326Q mutation found in patients with beta-ureidopropionase deficiencies

Theravance reports topline results from dose-ranging phase IIb trial of TD-4208 in COPD

Invion reports data from first two dose cohorts in phase I/II trial of INV-103 in SLE

Momenta Pharmaceuticals exercises option to acquire antibodies from AnaptysBio

Spectrum Pharmaceuticals to advance SPI-2012 to phase III

New indication for Spiriva Respimat approved in Europe

Ophthotech achieves milestone under Fovista agreement with Novartis

PharmAthene and Nanotherapeutics form biodefense development alliance

C3 Jian completes phase II trial of C16G2

Theravance presents promising data for the heterodimer antibiotic TD-1607

Neurodyn Life Sciences reports phase Ia data for Memogain

Update on FDA orphan drug status designations

FDA approves Astute Medical's NephroCheck acute kidney injury test

NIAID contracts Emergent BioSolutions to develop dry formulation of anthrax vaccine

Hyperion Therapeutics terminates development of DiaPep277 following evidence of misconduct

FDA advisory committee votes against recommending approval of nebivolol/valsartan